Healthcare / Medical DevicesKOSDAQ
$4250.00
-150.00 (-3.41%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 19%
FCF escenarios
weak_data · normalized FCF $-9.2B · quality 51.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
43/100
C
Piotroski
8/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$54.3B
P/E
9.8x
↓EV/EBITDA
5.0x
↓ROE
8.0%
↑Gross Margin
51.9%
↑Debt/Equity
0.38
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+16.3%
FCF CAGR
+80.3%
FCF margin
22.8%
FCF / Net income
3.65x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $100.43B · net income $6.26B · FCF $22.86B
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $100.43B | $100.43B | $85.59B | $92.05B | $63.91B |
| Net Income | $6.26B | $6.26B | $-2.58B | $4.06B | $1.78B |
| EBITDA | $14.53B | $14.53B | $9.86B | $15.67B | $9.95B |
| EPS | 435.00 | 435.00 | -202.00 | 252.00 | 146.00 |
| Gross Margin | 51.9% | 51.9% | 51.7% | 56.2% | 62.5% |
| Operating Margin | 9.3% | 9.3% | 3.9% | 7.7% | 9.1% |
| Net Margin | 6.2% | 6.2% | -3.0% | 4.4% | 2.8% |
| Balance Sheet | |||||
| Debt/Equity | 0.38 | 0.38 | 0.71 | 0.57 | 0.69 |
| Current Ratio | 1.83 | 1.83 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $22.86B | $22.86B | $-12.74B | $-9.19B | $3.90B |
| Returns | |||||
| ROE | 8.0% | 8.0% | -3.6% | 5.5% | 2.7% |
| Valuation | |||||
| P/E | 9.77 | 9.77 | — | 48.25 | 71.58 |
| EV/EBITDA | 5.01 | 5.01 | 10.63 | 14.10 | 15.78 |
| P/B | 0.78 | 0.78 | 0.98 | 2.65 | 1.94 |
| Growth & Yield | |||||
| Revenue Growth | 17.3% | 17.3% | -7.0% | 44.0% | — |
| EPS Growth | 315.3% | 315.3% | -180.2% | 72.6% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
-4.6%
EPS terminal req.
$377.12
Spread vs growth
320.0%
5Y implied EPS CAGR
1.0%
EPS terminal req.
$456.31
Spread vs growth
314.4%
10Y implied EPS CAGR
5.4%
EPS terminal req.
$734.89
Spread vs growth
310.0%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-32.4%
Start / end P/E
n/dx → n/dx
EPS bridge
-202.00 → 435.00
Residual
-32.4%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.